Viptin 50 MG


Viptin 50 MG


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)






Vildagliptin is demonstrated as an aide to eat less and work out to move forward glycemic control in patients with sort 2 diabetes mellitus as monotherapy and in double combination with Metformin, a Sulphonylurea, a Thiazolidinedione, or Affront when eat less, work out and a single antidiabetic specialist don’t result in satisfactory glycemic control.



Vildagliptin could be a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is accepted to apply its activities in patients with sort 2 diabetes by abating the inactivation of incretin hormones. Incretin hormones, counting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are discharged by the digestive system all through the day, and levels are expanded in reaction to a feast. These hormones are quickly inactivated by the protein, DPP-4. The incretins are part of an endogenous framework included within the physiologic control of glucose homeostasis. When blood glucose concentrations are typical or lifted, GLP-1 and GIP increment affront amalgamation and discharge from pancreatic beta cells by intracellular signaling pathways including cyclic AMP. GLP-1 too brings down glucagon discharge from pancreatic alpha cells, driving to decreased hepatic glucose generation. By expanding and drawing out dynamic incretin levels, Vildagliptin increments affront discharge and diminishes glucagon levels.


Administration & Dosage

The recommended dose of Vildagliptin is-

  • 50 mg or 100 mg daily for monotherapy.
  • 50 mg twice daily (morning and evening) when used in dual combination with Metformin or a Thiazolidinedione;
  • 50 mg once daily in the morning when used in dual combination with a Sulphonylurea.

Vildagliptin may be taken with or without a meal. No dosage adjustment is required in the elderly, or in patients with mild renal impairment.

Pediatric use: Vildagliptin is not recommended in patients 18 years of age.



In pharmacokinetic studies, no interactions were seen with pioglitazone, metformin, glibenclamide, digoxin, warfarin, amlodipine, ramipril, valsartan or simvastatin. As with other oral antidiabetic medicinal products the glucose-lowering effect of Vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.



Vildagliptin is contraindicated in patients with: Hypersensitivity to the dynamic substance or to any of the excipients Patients with direct to extreme renalImpairment Patients with Hepatic Impedance: patients with pre-treatment alanine aminotransferase (ALT) or aspartate aminotrasferase (AST) >3 times the upper constrain of typical (ULN). Patients with sort 1 diabetes.


Side Effects

The majority of adverse reactions were mild and transient, not requiring treatment discontinuations. A rare case of hepatic dysfunction is seen. Clinical trials of up to and more than 2 years duration did not show any additional safety signals or unforeseen risks when using this combination.


Pregnancy & Lactation

Vildagliptin should not be used in pregnancy. Vildagliptin should not be used during lactation.


Precautions & Warnings

Caution should be exercised in patients aged 75 years and older due to limited clinical experience. It is recommended that LFTs are monitored prior to initiation of Vildagliptin, at three-monthly intervals in the first year and periodically thereafter. If transaminase levels are increased, patients should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality returns to normal. If AST or ALT persists at 3xULN, Vildagliptin treatment should be stopped. Patients who develop jaundice or other signs of liver dysfunction should discontinue Vildagliptin. Following the withdrawal of treatment with Vildagliptin and LFT normalization, treatment with Vildagliptin should not be reinitiated. Due to limited clinical experience, use with caution in patients with congestive heart failure of New York Heart Association (NYHA) functional class I-II, and do not use in patients with NYHA functional class III IV.


Therapeutic Class

Dipeptidyl Peptidase-4 (DPP-4) inhibitor


Storage Conditions

Protect from light and moisture by storing below 30°C. Keep the medicine out of children’s reach.


Pharmaceutical Name

General Pharmaceuticals Ltd.